01370nas a2200277   4500000000100000008004100001653001200042653004400054653002600098100001800124700001000142700001300152700001800165700001300183700001600196700001300212700001300225700001200238700001500250245008500265856004700350300001000397490000700407520066400414022001401078       2016                            d10aleprosy10aDapsone hypersensitivity syndrome (DHS)10aFulminant myocarditis1 aHoogeveen R M1 aBom T1 aBoer H H1 aThurlings R M1 aWind B S1 aVries H J C1 aLent A U1 aBeuers U1 aWal A C1 aNellen F J00aA lethal case of the dapsone hypersensitivity syndrome involving the myocardium.  uhttp://www.njmonline.nl/getpdf.php?id=1679  a89-920 v743 a<p>In the Netherlands dapsone is used for the treatment of dermatitis herpetiformis, leprosy and Pneumocystis jiroveci pneumonia and prophylaxis in case of cotrimoxazole allergy. An idiosyncratic drug reaction, known as the dapsone hypersensitivity syndrome (DHS), appears in about 0.5-3.6% of persons treated with dapsone. DHS can be associated with fever, rash and systemic involvement. We present a 35-year-old woman who developed severe DHS seven weeks after starting dapsone. Six weeks after being discharged in a good clinical condition she died from fulminant myocarditis, 11 weeks after the first DHS symptoms and the discontinuation of dapsone.</p>
  a1872-9061